New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender

New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender

Nov 13, 2020
Source URL: https://qa1.novartis.us/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/new-novartis-analyses-investigational-inclisiran-demonstrate-consistently-effective-and-sustained-ldl-c-reduction-month-17-regardless-age-and-gender-0